Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 13/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 13/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15052336 | 0.97 | HIF1A (0.53) | HIF1AEPAS1HRH3ALDH1A1HTR2A | |
| SCHEMBL15052753 | 0.95 | HIF1A (0.55) | HIF1AEPAS1HTR2ACYP3A4CYP2D6 | |
| SCHEMBL15052429 | 0.80 | HIF1A (0.53) | HIF1AEPAS1HTR2A | |
| SCHEMBL14930293 | 0.79 | HIF1A (0.61) | HIF1AEPAS1 | |
| SCHEMBL15052571 | 0.79 | HIF1A (0.57) | HIF1AEPAS1 | |
| SCHEMBL2564150 | 0.77 | HIF1A (0.49) | HIF1AEPAS1HTR2AHTT | |
| SCHEMBL2564066 | 0.77 | ALDH1A1 (0.38) | HIF1AEPAS1HRH3ALDH1A1POLB | |
| SCHEMBL9032911 | 0.74 | HIF1A (0.54) | HIF1AEPAS1 | |
| SCHEMBL5868243 | 0.74 | HIF1A (0.54) | HIF1AEPAS1ALDH1A1POLBCYP3A4 | |
| SCHEMBL2561679 | 0.74 | HIF1A (0.68) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381260-B2 | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | EMORY UNIVERSITY (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | HIF1A, HIF1AN, HYOU1 | HIF1A 1/4885EPAS1 28/4885HRH3 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.